Non-invasive, real time optical imaging methods are particularly well suited for the in vivo follow up of the distribution of nucleic acids nanocarriers, their dissociation and finally the resulting gene expression or inhibition. Indeed, most small animal imaging devices are performing bioluminescence and fluorescence measurements without moving the animal, allowing a simple, rapid and cost effective method of investigation of several parameters at a time, in longitudinal experiments that can last for days or weeks.
INTRODUCTION
Optical imaging based on 2D Fluorescence reflectance (FRI), is a non-invasive method, that allows to follow molecules injected into a mouse in real time, at a good spatial (nm to mm range) and temporal resolution (µ to msec), a high sensibility (femto-to pico-molar range) and from whole-body down to the subcellular scale. However, the information that can be obtained through absorbing biological tissues is strongly depth-weighted and depends on the thickness and optical properties of the tissues to be imaged. This method is thus only semiquantitative. The tissues are less absorbing in a near-infrared (NIR) spectral window ranging from 650 nm to 900 nm and it is thus important to use adapted fluorophores whenever possible.
The recent description of increasing amounts of organic or in-organic NIR fluorochromes contributed to the development of optical imaging methods for the investigation of deep tissues (1, 2) . These fluorophores, or combination of them can be used for labeling molecules of interest and will accelerate significantly the preclinical studies. By separately labeling the vector and the nucleic acid using an adapted pair of fluorophores, we can provide direct information on the distribution of the intact particle, its capacity to release the nucleic acid, the subcellular distribution of each component, and finally a direct measure of the reporter gene expression.
Several reporter genes of the luciferase family are adapted to bioluminescence imaging in vivo (BLI), while the very commonly used fluorescent proteins like Green Fluorescent proteins (GFP), RedFP, etc…can be used in FRI but are more adapted for in vitro applications because they emit in the visible spectrum. ß-galactosidase, an enzyme encoded by the lacZ gene of Escherichia coli can also be followed in vivo using NIR substrates like DDAOG (3) .
Thus by combining FRI and BLI, we can obtain multiple information especially well suited for the evaluation of the biodistribution of lipid nanocapsules(LNC) or polyethilenimine (PEI) polyplexes, or cell penetrating peptides (CPPs), three non-viral systems well suited for the delivery of DNA and siRNA in mice (4-6).
MATERIALS

Fluorophores
Commercially available fluorophores are declined in a wide variety of wavelength, hydrophilicity and reactive moieties. Since the choice of absorption and emission wavelength mainly depends on the available apparatus, we will here focus on selection criteria for hydrophobicity/hydrophilicity and chemical reactivity ( Table 1 ).
FRET, dark dye quenching, and wavelength selection
Even with the right fluorophore, fluorescence imaging will only reveal the molecule location independently of the nanoparticle. Förster resonance energy transfer (FRET) occurs between a donor and a receptor dye within the range of the Förster radius, typically ranging from 5 to 10 nm depending on the pair considered. This property makes it a useful phenomenon to gather information in the nanometric range through spectroscopic methods. When donor and acceptor dyes are in close vicinity, excitation of the former can be passed to the latter via nonradiative pathways. Macroscopically, FRET is attested by a decrease of the donor fluorescence and an increase of the acceptor emission upon irradiation of the donor. It is therefore possible to know whether or not dyes are still encapsulated within a nanoparticle by studying its emission spectrum: upon excitation of the donor, free dyes will display normal donor fluorescence while nanoparticles will display strong acceptor emission.
Dark dye quenching is also based on FRET, except that the acceptor dye is non-fluorescent. In this case, the energy transfer result in a decrease of the donor emission while the acceptor remains non-fluorescent. This results in a simple on/off switch in fluorescence, where emission is recovered when the dyes are released from the nanoparticle. Though this method provide a more straightforward mean to track where and when the dyes escapes from the nanoparticle, it also means that (contrary to classical FRET method) circulating nanoparticles are non-fluorescent and can not be tracked through spectroscopic method unless a third dye is introduced.
To occur, FRET requires that spectral absorption of the acceptor overlaps sufficiently with the donor emission. Though precise calculations are required, this generally means that absorption peaks of the donor and acceptor should be spaced by approximately 50 to 100 nm.
On the one hand, with less than 50 nm, spectral overlap between donor and acceptor emissions might hinder FRET measurements. On the other hand, spectral differences of more than 100 nm will often result in low a spectral overlap, therefore very short Förster radii. The 
Nucleic acids
Two types of nucleic acids will be presented: DNA or/and siRNA. In each case, high-quality plasmids or small interfering RNA (siRNA) preparations should be used.
Plasmid reporter genes
To visualize the efficiency and biodistribution of in vivo gene delivery, different reporter genes can be used. For in vivo bioluminescence, plasmids encoding for firefly luciferase are very commonly used (pgWIZ-luciferase (GENLANTIS, San Diego, USA) by example). The bacterial ß-galactosidase gene expression can be detected in vivo using near infrared fluorescent imaging (NIR). For plasmid DNA, OD 260/280 ratio should be greater than 1.8. It is best to use DNA prepared in water, free of salt, RNAs, proteins or endotoxins.
Tracking of small interfering RNA (siRNA)
Concerning siRNA (21-23 nucleotides duplex RNA with symmetric 2 nucleotides 3' overhangs), we use high-quality desalted siRNA (PAGE or HPLC purified). As for primer/probe design, a G/C content around 50% is usually selected and oligonucleotides with three or more of any purinenucleotide in a row are avoided. Prediction algorithms provide some guidance for siRNA sequence selection (Note 1).
DiD-DNA-lipid nanocapsules (LNC) compounds
Lipoplexes compounds
Cationic lipids used are DOTAP (1,2-DiOleoyl-3-TrimethylAmmonium-Propane) and DOPE 
Special equipment
Size, polydispersity index, or surface charge (zeta potential) of DiD labeled DNA LNCs, post inserted or not, can be measured using a Malvern Zetasizer® (Nano Series DTS 1060, Malvern Instruments S.A., Worcestershire, UK).
Fluorescent labeling of peptide
For purification of CADY by semi-preparative reverse-phase high performance liquid chromatography (RP-HPLC), we use C18 column Interchrom UP5 WOD/25M Uptisphere 300 5 ODB, 250 mm x 21.2 mm. For labeling, we use maleimide dyes (maleimide-FITC or Maleimide-Alexa) from Molecular Probes. Inc (Invitrogen, Carlsbad, CA, USA).
PEI DNA complex
Polyethylenimine (PEI) is a linear cationic polymer widely used in vivo for delivery of many nucleic acid including plasmid DNA, oligonucleotides and siRNA without triggering an immune response. PEI is widely used in animal models and also in the clinic. For in vivo transfection, we use "in vivo-jetPEI™" (Polyplus-transfection, Ilkirch, France). "In vivo-jetPEI™" mediates efficient nucleic acid delivery in a wide range of tissues, using various delivery routes: intravenous (IV), intraperitoneal (IP), intratumoral, intracardiac, subcutaneous, topical, intrathecal, intra-cerebral, etc. Upon IV administration, high levels of nucleic acid delivery are achieved in the lung. Other organs such as heart, spleen, pancreas and liver are also transfected following IV injection. In addition "in vivo-jetPEI™" is an effective carrier for local gene delivery such as intratumoral or topical application on the skin.
More recently "in vivo-jetPEI™" has become a powerful tool for in vivo RNA interference experiments.
Animals
All animal experiments are conducted in agreement with the "Principles of laboratory animal care" (NIH publication No. 86-23, revised 1985) and approved by the local ethical Committee. Optical imaging experiments are conducted on female 6-8 weeks old nude mice.
D-Luciferin
Powder (Promega, Charbonnières, France) is dissolved in DPBS without CaCl 2 and MgCl 2 at 100 mg/mL.The solution is sterilized by filtrationacross a 0.2 µm membrane and stored at -80°Csheltered from light.
DDAOG
9H-(1,3-dichloro-9,9-dimethylacridin-2-one-7-yl) ß-D-galactopyranoside (Molecular Probes, Invitrogen, Carlsbad, CA, USA) is dissolved in DMSO/PBS v/v to get 5 mg/mL. 3. Six temperature heat-cooling cycles were applied between 20 and 60°C, still under magnetic stirring, to obtain a phase inversion from an oil-in-water to a water-in-oil emulsion. Change in color can be observed in a zone between these two emulsions. In this region, the system appeared translucent with blue glints, which is representative of microemulsions, this zone was called the phase inversion area (7) . After these temperature cycles, in the phase inversion zone, the mixture underwent a fast coolingdilution process with 500µl of cold water (4°C), leading to the formation of DiD labeled DNA LNCs in water (Note 5).
Fluorescence imaging set-up
Control the size, polydispersity and surface charge (zeta potential) of DiD labeled
DNA LNCs thanks to dynamic light scattering (DLS, size) and electrophoretic mobility (zeta potential) (ex. Malvern Zetasizer®, Nano Series DTS 1060, Malvern Instruments S.A., Worcestershire, UK).
Control the encapsulation properties of DiD labeled DNA LNCs thanks to electrophoresis migration of broken (Triton X100) or intact DNA LNCs in an agarose
gel (1%) containing ethidium bromide (method developed in (5, 8, 9) 2. Add DiD labeled DNA LNC suspension of a total volume of 2.5 ml per column. If the volume is less than 2.5 ml, then add buffer until the total volume of 2.5 ml is achieved.
3. Elute with buffer and collect the flow-through. The fractions containing DiD labeled DNA LNCs were collected. After this purification step, the LNC concentration was low; a concentration step was therefore required.
Add 12 ml maximum of collected fraction of DiD labeled DNA LNCs in a Amicon®
Ultra-15 centrifugal filter devices. 4. After this co-incubation step, mix by vortexing and put the tube in an ice bath.
Procedure for fluorescent labeling of cell penetrating peptides
Cell-penetrating peptides (CPP) constitute promising tools for non-invasive cellular import of siRNA. CPP-based strategies have been successfully applied for ex vivo and in vivo delivery of therapeutic siRNA molecules. Recently, a new peptide-based system, CADY, has been described for efficient delivery of siRNA. CADY is a secondary amphiphatic peptide able to form stable non-covalent complexes with siRNA and to improve their cellular uptake. It is possible to modify this peptide for following CADY/siRNA complexes in vivo.
The protocol described below outline (a) A general procedure suitable for conjugation of most thiol-reactive probes (iodoacetamides, maleimides) to peptides and (b) different procedures for peptide purifications.
1. CADY (20-residues: Ac-GLWRALWRLLRSLWRLLWRA-cya; MW: 2653 Da) was synthesized by solid-phase peptide synthesis using AEDI-expensin resin with (fluorenylmethoxy)-carbonyl (Fmoc) continuous (Pionner, Applied Biosystems, Foster city, CA) as described previously (10) . CADY was purified by semipreparative reverse-phase high performance liquid chromatography (RP-HPLC) and
identified by electrospray mass spectrometry and amino acid analysis (10) . The peptide is acetylated at its N-terminus and carried a cysteamide group at its Cterminus. 8. Allow the reaction to proceed for 2 hours at room temperature or overnight at 4°C.
Take
For more detail see The Handbook: A Guide to Fluorescent Probes and Labeling
Technologies (probes.invitrogen.com).
9. Upon completion of the reaction with the protein, an excess of glutathione, and 2-ßmercaptoethanol, is present, ensuring that no reactive species are formed during the purification step.
10. Fluorescently labeled peptide can be separate on a Sephadex G-25 columngel filtration column equilibrated in phosphate buffer saline (NAP-10 column). However, for in cellular or in vivo imaging, Fluorescently labeled peptides were further purified by RP-HPLC using a C18 reverse-phase HPLC column (Interchrom UP5 HDO/25M
Modulo-cart Uptisphere, 250 mm x 10 mm) and identified by electrospray mass spectrometry.
11. The degree of labeling can be calculated using the following formula:
where Ax = the absorbance value of the dye at the absorption maximum wavelength. And e= molar extinction coefficient of the dye or reagent at the absorption maximum wavelength (according to The Handbook: A Guide to Fluorescent Probes and Labeling Technologies).
The procedure for CADY-siRNA complex formation constitutes a major factor in the success and efficiency of CADY technology and should be followed carefully. It was well described previously in (11).
Synthesis of PEI FluoR (Figure 1)
A solution (1. The preparation of the PEI FluoR/nucleic acid complexes should be performed in a laminar flow hood using the sterile 10 % glucose solution.
1. Dilute the nucleic acid (plasmid DNA or siRNA; (Table 4 ).
6. The biodistribution of PEI-FluoR can be followed as early as 1 to 4 h following injection, using fluorescence of the whole animal or slices of fixed tissues depending on the target organ.
7. Monitor gene expression as required at the appropriate time point (1-96 h after the last injection) depending on the mode of injection and the targeted organ.
With the current formulation and delivery approaches employed today, silencing can be achieved in several tissues and cell types, most notably through direct delivery of siRNA to the back of the eye, to the central nervous system, and to lung epithelial cells, and through systemic delivery of siRNA to hepatocytes and tumor cells. 
Pharmacokinetic study by in vivo Fluorescence
Luc gene transfer follow up by in vivo Bioluminescence imaging
In vivo luciferase expression is monitored by bioluminescence 24 hours after luciferase gene transfer in vivo.
1. The day of experimentation the solution is diluted to 10 mg/mL in DPBS without CaCl 2 and MgCl 2 and is kept sheltered from light.
2. Vigil mice are injected intraperitonealy with D-Luciferin (150 mg/kg) just before anesthesia (isoflurane 4% for induction and 1.5% thereafter). Luciferase activity measurement (brain, heart, lungs, liver, spleen, pancreas, stomach, guts, kidneys, suprarenal glands, ovaries, uterus, muscle, fat, skin, lymph nodes).
Five minutes after
LacZ gene transfer follow up by in vivo Fluorescence Reflectance imaging
In vivo ß-Gal expression is monitored by NIR fluorescence 24 hours after LacZ gene transfer in vivo. 
